SG11201811491YA - Quinazoline and indole compounds to treat medical disorders - Google Patents
Quinazoline and indole compounds to treat medical disordersInfo
- Publication number
- SG11201811491YA SG11201811491YA SG11201811491YA SG11201811491YA SG11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA SG 11201811491Y A SG11201811491Y A SG 11201811491YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- pct
- applicant
- new haven
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 01111111HH11111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/005552 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: A61K 31/517 (2006.01) C07D 401/14 (2006.01) Published: A61K 31/395 (2006.01) — with international search report (Art 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/039587 amendments (Rule 48.2(h)) (22) International Filing Date: 27 June 2017 (27.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/355,273 27 June 2016 (27.06.2016) US 62/471,799 15 March 2017 (15.03.2017) US (71) Applicant: ACHILLION PHARMACEUTICALS, INC. [US/US]; 300 George Street, New Haven, CT 06511 (US). (72) Inventors: WILES, Jason Allan; c/o Achillion Pharma- ceuticals, Inc., 300 George Street, New Haven, CT 06511 _ (US). PHADKE, Avinash; c/o Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, CT 06511 (US). — = Agent: BELLOWS, Brent R. et al.; Knowles Intellectu- (74) al Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (81) = — = = = = = = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = = = — = — 1-1 ..! Declarations under Rule 4.17: ei — as to applicant's entitlement to apply for and be granted a kir) patent (Rule 4.170) ir) — as to the applicant's entitlement to claim the priority of the kir) 0 earlier application (Rule 4.17(iii)) 0 --.... 00 1-1 (54) Title: QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS 0 ei (57) : Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662355273P | 2016-06-27 | 2016-06-27 | |
US201762471799P | 2017-03-15 | 2017-03-15 | |
PCT/US2017/039587 WO2018005552A1 (en) | 2016-06-27 | 2017-06-27 | Quinazoline and indole compounds to treat medical disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811491YA true SG11201811491YA (en) | 2019-01-30 |
Family
ID=60787571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811491YA SG11201811491YA (en) | 2016-06-27 | 2017-06-27 | Quinazoline and indole compounds to treat medical disorders |
Country Status (13)
Country | Link |
---|---|
US (3) | US10961252B2 (en) |
EP (2) | EP3939591A1 (en) |
JP (2) | JP7057290B2 (en) |
KR (1) | KR20190036520A (en) |
CN (1) | CN109414441A (en) |
AU (1) | AU2017290593A1 (en) |
CA (1) | CA3029262A1 (en) |
ES (1) | ES2902006T3 (en) |
IL (1) | IL263783A (en) |
MX (1) | MX2018016046A (en) |
RU (1) | RU2018145364A (en) |
SG (1) | SG11201811491YA (en) |
WO (1) | WO2018005552A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397592A (en) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
MX2018016046A (en) * | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders. |
KR102632860B1 (en) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for the treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
WO2018160892A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
AU2019336238A1 (en) | 2018-09-06 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of Complement factor D inhibitors |
EP3856164A4 (en) | 2018-09-25 | 2022-07-13 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
BR112022010078A2 (en) * | 2019-11-26 | 2022-12-13 | Omeros Corp | METHODS FOR TREATMENT OF A HUMAN SUBJECT SUFFERING FROM IDIOPATHIC PNEUMONIA SYNDROME, CAPILLARY LEAK SYNDROME, FLUID OVERLOAD AND GRAFT SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION |
US20210335448A1 (en) * | 2020-04-27 | 2021-10-28 | Advaita Corporation | Methods of identifying treatments using differentially expressed genes |
EP4194449A4 (en) * | 2020-08-07 | 2024-03-20 | Shanghai Meiyue Biotech Dev Co Ltd | Heterocyclic compound, preparation method therefor and use thereof |
EP4194451A1 (en) * | 2020-08-07 | 2023-06-14 | Shanghai Meiyue Biotech Development Co., Ltd. | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof |
WO2022143940A1 (en) * | 2020-12-30 | 2022-07-07 | 南京明德新药研发有限公司 | Series of piperidine-substituted benzoic acid compounds, and use thereof |
CN112940825B (en) * | 2021-02-06 | 2022-05-13 | 中国科学院兰州化学物理研究所 | Application of silicon phosphide quantum dots as lubricating oil additive, lubricating oil and preparation method and application thereof |
WO2022218429A1 (en) * | 2021-04-16 | 2022-10-20 | 正大天晴药业集团股份有限公司 | Bicyclic substituted aromatic carboxylic acid compounds |
CA3222144A1 (en) * | 2021-06-03 | 2022-12-08 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
WO2023020566A1 (en) * | 2021-08-18 | 2023-02-23 | 四川海思科制药有限公司 | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine |
TW202334121A (en) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
TW202329939A (en) * | 2022-01-26 | 2023-08-01 | 大陸商上海美悦生物科技發展有限公司 | Salt form and crystal form of complement factor b inhibitor and preparation method and use thereof |
CN114921071B (en) * | 2022-03-13 | 2023-07-14 | 宁波大学 | Antibacterial nanocellulose/PHBV composite material and preparation method thereof |
WO2023237041A1 (en) * | 2022-06-10 | 2023-12-14 | 正大天晴药业集团股份有限公司 | Bicyclic substituted aromatic carboxylic acid ester compound |
WO2023246677A1 (en) * | 2022-06-20 | 2023-12-28 | 深圳信立泰药业股份有限公司 | Indole-phenylpiperidine compound, method for preparing same, and use thereof |
WO2024002353A1 (en) * | 2022-06-30 | 2024-01-04 | 江苏恒瑞医药股份有限公司 | Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same |
WO2024017299A1 (en) * | 2022-07-20 | 2024-01-25 | 正大天晴药业集团股份有限公司 | Crystal of bridged heterocycle substituted benzoic acid derivative or salt thereof, and preparation method therefor |
WO2024051849A1 (en) * | 2022-09-10 | 2024-03-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof |
Family Cites Families (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB929405A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Processes for the encapsulation of particles |
GB929401A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Encapsulated emulsions and processes for their preparation |
GB969808A (en) | 1962-06-08 | 1964-09-16 | Boots Pure Drug Co Ltd | Anthelmintic compositions and compounds |
IT1148784B (en) | 1980-04-09 | 1986-12-03 | Eurand Spa | PROCEDURE FOR THE PREPARATION OF MICRO CAPSULES IN A LIQUID VEHICLE |
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
US5110927A (en) | 1987-12-31 | 1992-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Prazosin analog with increased selectivity and duration of action |
JP2528706B2 (en) | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | Pharmaceutical composition of dihydropyridine compound |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5013557A (en) | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
ATE159426T1 (en) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING A SOLID DISPERSION |
TW209174B (en) | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
SE9401109D0 (en) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
SE9401108D0 (en) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
IT1271679B (en) | 1994-07-18 | 1997-06-04 | Mediolanum Farmaceutici Srl | PHENYL CARBAMATE DERIVATIVES FOR USE AS AN ANTICOLINESTERASIC |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
KR100424931B1 (en) | 1994-12-19 | 2004-07-05 | 다이이찌 세이야꾸 가부시기가이샤 | Sustained release granules and preparation method |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
DE69628276T2 (en) | 1995-07-26 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | PREPARATION OF XANTHINE DERIVATIVES AS A FIXED DISPERSION |
US5747490A (en) | 1995-09-29 | 1998-05-05 | Merck & Co., Inc. | Alpha 1b adrenergic receptor antagonists |
EP0853479A4 (en) | 1995-09-29 | 2001-04-11 | Merck & Co Inc | ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
GB9526546D0 (en) | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
WO1998000170A1 (en) | 1996-07-01 | 1998-01-08 | Universiteit Utrecht | Hydrolysable hydrogels for controlled release |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
EP0842657A1 (en) | 1996-11-19 | 1998-05-20 | OctoPlus B.V. | Microspheres for controlled release and processes to prepare these microspheres |
AU7808198A (en) | 1997-06-03 | 1998-12-21 | Biocryst Pharmaceuticals, Inc. | Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
JPH1123485A (en) | 1997-07-07 | 1999-01-29 | Tani Denki Kogyo Kk | Method and apparatus for inspecting substrate |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
DK0901786T3 (en) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Solid pharmaceutical dispersions with increased bioavailability |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6410561B1 (en) | 1998-03-26 | 2002-06-25 | Japan Tobacco Inc. | Amide derivatives and nociceptin antagonists |
AU1705100A (en) | 1998-10-09 | 2000-05-01 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
GB9827145D0 (en) | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
JP2000281660A (en) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | Quinazoline derivative |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
IT1312310B1 (en) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION |
GB9927011D0 (en) | 1999-11-16 | 2000-01-12 | Advanced Phytonics Ltd | Method for the production of particles |
AU2583401A (en) | 1999-12-20 | 2001-07-03 | Cocensys, Inc. | Process for producing nanometer particles by fluid bed spray-drying |
KR100523127B1 (en) | 1999-12-23 | 2005-10-20 | 화이자 프로덕츠 인코포레이티드 | Hydrogel-driven drug dosage form |
AU784340B2 (en) | 1999-12-23 | 2006-03-16 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
CA2400172C (en) | 2000-02-28 | 2010-04-20 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
AU2001240150A1 (en) | 2000-03-13 | 2001-09-24 | Chemrx Advanced Technologies, Inc. | Quinazoline synthesis |
WO2001074400A1 (en) | 2000-04-03 | 2001-10-11 | Santen Pharmaceutical Co., Ltd. | Transporters and drug delivery system by using the same |
GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
GB0009469D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
IL153705A0 (en) | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
GB2364919A (en) | 2000-07-21 | 2002-02-13 | Cambridge Consultants | Inhalers |
GB0021024D0 (en) | 2000-08-29 | 2000-10-11 | Glaxo Group Ltd | Inhalation device |
ES2382636T3 (en) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Method for producing compositions for improved administration of bioactive molecules |
DE60140268D1 (en) | 2000-11-30 | 2009-12-03 | Vectura Ltd | PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION |
US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
BR0307516A (en) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Immediate release dosage forms containing dispersions of a solid drug |
EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | Open chain prolyl urea-related modulators of androgen receptor function |
US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
JP2007505831A (en) | 2003-09-15 | 2007-03-15 | ベクトゥラ・リミテッド | Pharmaceutical composition for treating premature ejaculation by pulmonary inhalation |
US7585517B2 (en) | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
EP1694731B1 (en) | 2003-09-23 | 2012-03-28 | University Of North Carolina At Chapel Hill | Photocurable perfluoropolyethers for use as novel materials in microfluidic devices |
SE0302665D0 (en) | 2003-10-07 | 2003-10-07 | Astrazeneca Ab | Novel Process |
WO2005044186A2 (en) | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same |
KR102005840B1 (en) | 2003-12-19 | 2019-07-31 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
WO2005072710A2 (en) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
GB0407627D0 (en) | 2004-04-02 | 2004-05-05 | Vectura Ltd | Corkscrew pump |
CA2563895C (en) | 2004-04-13 | 2012-10-16 | Synta Pharmaceuticals Corp. | Disalt inhibitors of il-12 production |
ES2246694B1 (en) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | PEGILATED NANOPARTICLES. |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
BRPI0510485A (en) | 2004-04-30 | 2007-11-13 | Allergan Inc | biodegradable intravitreal tyrosine kinase inhibitor implants |
JP2007269629A (en) | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | Quinazoline derivative |
PL370285A1 (en) | 2004-09-23 | 2006-04-03 | Glaxosmithkline Pharmaceuticals Spółka Akcyjna | Powder inhaler |
EP1855652B1 (en) | 2005-01-28 | 2015-12-02 | Bend Research, Inc | Drying of drug-containing particles |
WO2006082518A1 (en) | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
MX2007016039A (en) | 2005-06-17 | 2008-10-27 | Univ North Carolina | Nanoparticle fabrication methods, systems, and materials. |
EP2537657A3 (en) | 2005-08-09 | 2016-05-04 | The University of North Carolina At Chapel Hill | Methods and materials for fabricating microfluidic devices |
US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
WO2007056561A2 (en) | 2005-11-09 | 2007-05-18 | Liquidia Technologies, Inc. | Medical device, materials, and methods |
JP2009520700A (en) | 2005-12-21 | 2009-05-28 | ペインセプター ファーマ コーポレーション | Compositions and methods for modulating gated ion channels |
US20070149593A1 (en) | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US8944804B2 (en) | 2006-01-04 | 2015-02-03 | Liquidia Technologies, Inc. | Nanostructured surfaces for biomedical/biomaterial applications and processes thereof |
WO2007084418A2 (en) | 2006-01-13 | 2007-07-26 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
CN101443004B (en) | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | Formulations and methods for vascular permeability-related diseases or conditions |
US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
WO2007133808A2 (en) | 2006-05-15 | 2007-11-22 | Liquidia Technologies, Inc. | Nano-particles for cosmetic applications |
WO2008003702A2 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine h4 receptor |
WO2008013952A2 (en) | 2006-07-27 | 2008-01-31 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells |
GB0617480D0 (en) | 2006-09-06 | 2006-10-18 | Univ Sheffield | Novel nanoparticles |
EP2061433B1 (en) | 2006-09-08 | 2011-02-16 | Johns Hopkins University | Compositions for enhancing transport through mucus |
US9022970B2 (en) | 2006-10-16 | 2015-05-05 | Alcon Research, Ltd. | Ophthalmic injection device including dosage control device |
CA2668814A1 (en) | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
WO2008100304A2 (en) | 2006-11-15 | 2008-08-21 | The University Of North Carolina At Chapel Hill | Polymer particle composite having high fidelity order, size, and shape particles |
EP2134173A4 (en) | 2007-03-01 | 2010-11-10 | Wellstat Ophthalmics Corp | Treatment of diseases characterized by inflammation |
ES2627233T3 (en) | 2007-10-12 | 2017-07-27 | Massachusetts Institute Of Technology | Vaccine Nanotechnology |
WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
EP2276420B1 (en) | 2008-04-04 | 2021-10-06 | Journey1, Inc. | Device to treat an eye having an epithelium with a defect |
WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
US8945527B2 (en) | 2008-04-25 | 2015-02-03 | The University Of North Carolina At Chapel Hill | Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates |
EP2133334A1 (en) | 2008-06-09 | 2009-12-16 | DAC S.r.l. | Heterocyclic derivatives as HDAC inhibitors |
WO2010009087A1 (en) | 2008-07-15 | 2010-01-21 | Eyegate Pharmaceuticals, Inc. | Iontophoretic delivery of a controlled-release formulation in the eye |
KR20110074766A (en) | 2008-10-08 | 2011-07-01 | 아스트라제네카 아베 | Inhalation device and method of dispensing medicament |
KR101690643B1 (en) | 2008-12-05 | 2016-12-28 | 리퀴디아 테크놀로지스 인코포레이티드 | Method for producing patterned materials |
CN102271676B (en) | 2008-12-30 | 2014-07-23 | 希尔氏宠物营养品公司 | Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
WO2010088548A1 (en) | 2009-01-29 | 2010-08-05 | Forsight Labs, Llc | Posterior segment drug delivery |
US20120052041A1 (en) | 2009-02-04 | 2012-03-01 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
EP2396316B1 (en) * | 2009-02-10 | 2015-07-01 | Janssen Pharmaceutica, N.V. | Quinazolinones as prolyl hydroxylase inhibitors |
AU2010213840B2 (en) | 2009-02-10 | 2014-03-20 | Eyepoint Pharmaceuticals Us, Inc. | Ocular trocar assembly |
EP2401027B1 (en) | 2009-02-26 | 2017-11-01 | The University of North Carolina At Chapel Hill | Interventional drug delivery system |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
WO2010141729A1 (en) | 2009-06-03 | 2010-12-09 | Forsight Labs, Llc | Anterior segment drug delivery |
JP5656996B2 (en) | 2009-07-13 | 2015-01-21 | ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル | Engineered aerosol particles and related methods |
TWI492769B (en) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | Injectable aqueous ophthalmic composition and method of use therefor |
US9498385B2 (en) | 2009-10-23 | 2016-11-22 | Nexisvision, Inc. | Conformable therapeutic shield for vision and pain |
NO2490635T3 (en) | 2009-10-23 | 2018-02-03 | ||
TWI478730B (en) | 2009-12-03 | 2015-04-01 | Alcon Res Ltd | Ophthalmic emulsion |
WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
WO2011140203A2 (en) | 2010-05-05 | 2011-11-10 | Alcon Research, Ltd. | Stabilized ophthalmic galactomannan formulations |
WO2011153349A1 (en) | 2010-06-02 | 2011-12-08 | Alcon Research, Ltd. | Ophthalmic compositions comprising pbo-peo-pbo block copolymers |
WO2012019047A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Subconjunctival implant for posterior segment drug delivery |
CN105435338B (en) | 2010-08-05 | 2019-03-26 | 弗赛特影像4股份有限公司 | Injector apparatus and method for drug conveying |
PL2600812T3 (en) | 2010-08-05 | 2022-01-24 | Forsight Vision4, Inc. | Apparatus to treat an eye |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
WO2012031129A2 (en) | 2010-09-03 | 2012-03-08 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
AU2011323250B2 (en) | 2010-11-05 | 2015-11-19 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
US20140033800A1 (en) | 2010-11-11 | 2014-02-06 | Forsight Vision4, Inc. | Methods and apparatus to determine diffusion properties of porous structures for drug delivery |
TW201304822A (en) | 2010-11-15 | 2013-02-01 | Vectura Ltd | Compositions and uses |
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
PE20140471A1 (en) | 2011-01-04 | 2014-04-13 | Novartis Ag | MODULATORS OF THE COMPLEMENT ROUTE AND USES OF THEM |
WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
WO2012145801A1 (en) | 2011-04-29 | 2012-11-01 | Jagat Rakesh Kanwar | Nanoparticle |
SG194780A1 (en) | 2011-05-05 | 2013-12-30 | Wellstat Immunotherapeutics Llc | Complement factor b analogs and their uses |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
MX2012007705A (en) | 2011-06-29 | 2012-12-28 | Rehrig Pacific Co | Crate with retractable wall. |
JP5721197B2 (en) | 2011-06-29 | 2015-05-20 | Necソリューションイノベータ株式会社 | Three-dimensional feature data generation device, three-dimensional feature data generation method, and three-dimensional feature data generation program |
CN106073986B (en) | 2011-09-14 | 2019-01-11 | 弗赛特影像5股份有限公司 | The device for treating the eyes of patient |
GB201115874D0 (en) | 2011-09-14 | 2011-10-26 | Astrazeneca Ab | Inhaler |
SI2755600T1 (en) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Fluid exchange apparatus |
WO2013082111A2 (en) | 2011-11-29 | 2013-06-06 | The University Of North Carolina At Chapel Hill | Geometrically engineered particles and methods for modulating macrophage or immune responses |
CN102516232A (en) | 2011-12-14 | 2012-06-27 | 无锡美克赛医药科技有限公司 | ErbB2 micro-molecular selective inhibitor and application thereof |
US20140329913A1 (en) | 2011-12-14 | 2014-11-06 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
PT2797652T (en) | 2011-12-27 | 2019-02-19 | Vectura Gmbh | Inhalation device with feedback system |
CN104936620B (en) | 2012-01-19 | 2019-08-09 | 约翰霍普金斯大学 | Enhance the nanoparticle composite of transmucosal |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
JP6174056B2 (en) | 2012-03-09 | 2017-08-02 | ベクチュラ・ゲーエムベーハー | Inhalation device and mixing channel for inhalation device |
WO2013138343A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
AU2013256130B2 (en) | 2012-05-03 | 2017-12-21 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
JP6180514B2 (en) | 2012-05-04 | 2017-08-16 | ノバルティス アーゲー | Complement pathway modulators and uses thereof |
US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
JP6163205B2 (en) | 2012-06-20 | 2017-07-12 | ノバルティス アーゲー | Complement pathway modulators and uses thereof |
US9468661B2 (en) | 2012-06-28 | 2016-10-18 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US9487483B2 (en) | 2012-06-28 | 2016-11-08 | Novartis Ag | Complement pathway modulators and uses thereof |
KR20150035766A (en) | 2012-06-28 | 2015-04-07 | 노파르티스 아게 | Pyrrolidine derivatives and their use as complement pathway modulators |
ES2648962T3 (en) | 2012-06-28 | 2018-01-09 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
ES2644700T3 (en) | 2012-06-28 | 2017-11-30 | Novartis Ag | Pyrrolidine derivatives and their use as modulators of the complement pathway |
EP2867226B1 (en) | 2012-06-28 | 2018-11-14 | Novartis AG | Complement pathway modulators and uses thereof |
WO2014005150A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof |
WO2014002059A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide |
EA201590200A1 (en) | 2012-07-12 | 2015-08-31 | Новартис Аг | MODULATORS OF THE COMPLEMENT ACTIVATION WAY AND THEIR APPLICATION |
ES1077714Y (en) | 2012-07-31 | 2012-12-20 | Gutierrez Jose Ramon Perez | Wooden container |
WO2014035876A1 (en) | 2012-08-27 | 2014-03-06 | William Marsh Rice University | Heat-inactivated complement factor b compositions and methods |
EP2895146A1 (en) | 2012-09-17 | 2015-07-22 | BIND Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
WO2014047439A1 (en) | 2012-09-20 | 2014-03-27 | Akina, Inc. | Biodegradable microcapsules containing filling material |
WO2014066775A1 (en) | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
PT2724741T (en) | 2012-10-26 | 2017-08-02 | Vectura Gmbh | Inhalation device for use in aerosol therapy |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
WO2014143638A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
CN105246438B (en) | 2013-03-28 | 2018-01-26 | 弗赛特影像4股份有限公司 | For conveying the ophthalmic implant of therapeutic substance |
WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
JO3425B1 (en) | 2013-07-15 | 2019-10-20 | Novartis Ag | Piperidinyl indole derivatives and their use as complement factor b inhibitors |
TW201546030A (en) | 2013-07-18 | 2015-12-16 | Novartis Ag | Aminomethyl-biaryl derivatives complement factor D inhibitors and uses thereof |
EP3043827B1 (en) | 2013-09-13 | 2019-07-03 | Ionis Pharmaceuticals, Inc. | Modulators of complement factor b |
AU2014334636A1 (en) | 2013-10-15 | 2016-06-02 | Forsight Vision5, Inc. | Formulations and methods for increasing or reducing mucus |
US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
US20160302965A1 (en) | 2013-12-06 | 2016-10-20 | Forsight Vision4, Inc. | Implantable therapeutic devices |
JP6546194B2 (en) | 2013-12-06 | 2019-07-17 | アラーガン、インコーポレイテッドAllergan,Incorporated | Anterior chamber implant for treating ocular conditions |
MX2018016046A (en) * | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders. |
-
2017
- 2017-06-27 MX MX2018016046A patent/MX2018016046A/en unknown
- 2017-06-27 ES ES17821106T patent/ES2902006T3/en active Active
- 2017-06-27 CA CA3029262A patent/CA3029262A1/en not_active Abandoned
- 2017-06-27 RU RU2018145364A patent/RU2018145364A/en not_active Application Discontinuation
- 2017-06-27 CN CN201780039962.XA patent/CN109414441A/en active Pending
- 2017-06-27 WO PCT/US2017/039587 patent/WO2018005552A1/en unknown
- 2017-06-27 JP JP2018567716A patent/JP7057290B2/en active Active
- 2017-06-27 AU AU2017290593A patent/AU2017290593A1/en not_active Abandoned
- 2017-06-27 SG SG11201811491YA patent/SG11201811491YA/en unknown
- 2017-06-27 KR KR1020197002194A patent/KR20190036520A/en unknown
- 2017-06-27 EP EP21195603.2A patent/EP3939591A1/en active Pending
- 2017-06-27 EP EP17821106.6A patent/EP3448389B1/en active Active
-
2018
- 2018-12-18 IL IL263783A patent/IL263783A/en unknown
- 2018-12-19 US US16/226,378 patent/US10961252B2/en active Active
-
2020
- 2020-01-28 US US16/774,117 patent/US11248000B2/en active Active
-
2021
- 2021-12-29 US US17/564,446 patent/US20220119400A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063981A patent/JP2022091984A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3448389A4 (en) | 2019-10-30 |
JP2022091984A (en) | 2022-06-21 |
JP7057290B2 (en) | 2022-04-19 |
ES2902006T3 (en) | 2022-03-24 |
US20200165262A1 (en) | 2020-05-28 |
WO2018005552A1 (en) | 2018-01-04 |
US20220119400A1 (en) | 2022-04-21 |
IL263783A (en) | 2019-01-31 |
MX2018016046A (en) | 2019-05-02 |
CA3029262A1 (en) | 2018-01-04 |
JP2019527203A (en) | 2019-09-26 |
US11248000B2 (en) | 2022-02-15 |
AU2017290593A1 (en) | 2019-01-03 |
US20190135825A1 (en) | 2019-05-09 |
CN109414441A (en) | 2019-03-01 |
EP3448389A1 (en) | 2019-03-06 |
US10961252B2 (en) | 2021-03-30 |
RU2018145364A (en) | 2020-07-28 |
KR20190036520A (en) | 2019-04-04 |
EP3939591A1 (en) | 2022-01-19 |
EP3448389B1 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201902531QA (en) | Liquid pharmaceutical composition | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
SG11201903230QA (en) | TCRa HOMING ENDONUCLEASE VARIANTS | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |